Stock Markets November 19, 2026 03:49 AM

Evotec Shares Jump After FDA Clears Second IND From BMS Collaboration

Clinical progress, buyback completion and a price-target upgrade combine to lift Frankfurt-listed shares

By Caleb Monroe
Share
Twitter Reddit Facebook LinkedIn

Evotec rose 3.6% after the U.S. FDA accepted a second Investigational New Drug application from its protein degradation partnership with Bristol Myers Squibb, with the new molecular glue candidate slated to enter Phase 1 testing in 2027. The announcement, the close of a share-repurchase program and an analyst price-target upgrade pushed the stock to an intraday high of 82.6

Evotec Shares Jump After FDA Clears Second IND From BMS Collaboration
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • FDA acceptance of a second IND from the Evotec-Bristol Myers Squibb protein degradation collaboration, with a molecular glue candidate aimed at Phase 1 testing in 2027.
  • Completion of a share repurchase program in which 365,000 shares were bought on Xetra between November 10 and 13; those shares are to be converted into ADSs for an employee equity program, signaling management confidence.
  • Broader market strength - S&P 500 up 1.0%, Nasdaq up 1.8%, and a positive DAX - along with an analyst price-target upgrade, supported the rally in Evotec shares.

Evotec AG shares climbed 3.6% on the session after the company confirmed that the U.S. Food and Drug Administration has accepted a second Investigational New Drug application stemming from its strategic protein degradation collaboration with Bristol Myers Squibb. The submission relates to a molecular glue candidate that is targeted to begin Phase 1 clinical testing in 2027.

Company commentary described the acceptance as evidence of the productivity of the collaboration's molecular glue discovery platform and its potential to address patient populations with unmet medical needs. That clinical milestone was the most direct driver cited for investor interest in the stock on the day.

Alongside the regulatory news, Evotec said it had finished a share repurchase program. The company bought 365,000 shares on Xetra between November 10 and 13. Those repurchased shares are intended to be converted into American Depositary Shares for use in an employee equity program. Management framed the buyback's completion as an indication of confidence in the share price at current levels.

Market-wide strength reinforced the positive tone for Evotec. U.S. indexes traded higher, with the S&P 500 up 1.0% and the Nasdaq rising 1.8%, helping lift sentiment across global risk assets, including European biotechnology stocks. Germany's DAX index also moved into positive territory, providing a constructive backdrop for shares listed in Frankfurt.

These factors coincided with at least one analyst increasing a price target for Evotec, and together they pushed the stock up to a session high of 82.6. That intraday peak remains substantially below the company's 52-week high of 6.73, but it is well above the 52-week low of .406 recorded earlier this year.

Investors therefore reacted to a convergence of events: a regulatory acceptance that advances a program out of preclinical stages, the formal close of a buyback aimed at supporting employee compensation in ADS form, and an analyst reassessment of the company's valuation. Each element contributed to improved market sentiment for the stock during the trading session.

While the FDA acceptance sets a concrete near-term milestone - the planned Phase 1 start in 2027 - the company and its investors will continue to monitor subsequent clinical and market developments as they unfold.


Note on market context: The price moves described occurred amid broader equity gains led by U.S. benchmarks and positive trading in European markets, factors that helped amplify demand for biotechnology and pharma-related equities on the day.

Risks

  • Clinical and regulatory uncertainty remains until the molecular glue candidate progresses through Phase 1 and subsequent trial stages - this affects biotech and pharmaceutical sectors.
  • Market sentiment can be influenced by broader equity movements; a reversal in U.S. or European indices could remove the favorable backdrop that helped lift Evotec shares - this impacts equity and biotech sectors.
  • Despite the intraday gain, the stock remains far below its 52-week high, indicating potential volatility and valuation gap risk for investors in Evotec equity.

More from Stock Markets

Toyota Issues Recall for 314,029 U.S. Vehicles Over Potential Takata Air Bag Hazard Nov 19, 2026 Palantir’s Best Quarter Yet Still Sparks a Stock Sell-Off Nov 19, 2026 Dell’s $95 Billion AI Backlog Tests Low-Margin Hardware Economics Nov 19, 2026 Amneal Rockets 64% as Moderna Slides: Complex Generics Power Near-Term Gains Amid Balance-Sheet Questions Nov 19, 2026 Bloom Energy Faces Market Scepticism Despite Rapid AI-Driven Order Flow Nov 19, 2026